Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients.
Oyaert M, De Scheerder MA, Van Herrewege S, Laureys G, Van Assche S, Cambron M, Naesens L, Hoste L, Claes K, Haerynck F, Kerre T, Van Laecke S, Jacques P, Padalko E. Oyaert M, et al. Among authors: de scheerder ma. Eur J Clin Microbiol Infect Dis. 2024 Jan;43(1):177-185. doi: 10.1007/s10096-023-04701-x. Epub 2023 Nov 13. Eur J Clin Microbiol Infect Dis. 2024. PMID: 37953413
Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients.
Oyaert M, De Scheerder MA, Van Herrewege S, Laureys G, Van Assche S, Cambron M, Naesens L, Hoste L, Claes K, Haerynck F, Kerre T, Van Laecke S, Van Biesen W, Jacques P, Verhasselt B, Padalko E. Oyaert M, et al. Among authors: de scheerder ma. Front Immunol. 2022 Mar 22;13:858399. doi: 10.3389/fimmu.2022.858399. eCollection 2022. Front Immunol. 2022. PMID: 35401575 Free PMC article.
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial.
Tobback E, Degroote S, Buysse S, Delesie L, Van Dooren L, Vanherrewege S, Barbezange C, Hutse V, Romano M, Thomas I, Padalko E, Callens S, De Scheerder MA. Tobback E, et al. Among authors: de scheerder ma. Int J Infect Dis. 2022 Sep;122:628-635. doi: 10.1016/j.ijid.2022.06.054. Epub 2022 Jul 5. Int J Infect Dis. 2022. PMID: 35803469 Free PMC article. Clinical Trial.
HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs.
De Scheerder MA, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, Rutsaert S, Verhofstede C, Kerre T, Malfait T, Hemelsoet D, Coppens M, Dhondt A, De Looze D, Vermassen F, Lemey P, Palmer S, Vandekerckhove L. De Scheerder MA, et al. Among authors: de looze d. Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7. doi: 10.1016/j.chom.2019.08.003. Epub 2019 Aug 27. Cell Host Microbe. 2019. PMID: 31471273 Free PMC article.
Tissue is the issue: when a second biopsy reveals the true diagnosis.
Bogaert AM, Hoorens A, Praet M, Van Dorpe J, Poppe B, De Scheerder MA. Bogaert AM, et al. Among authors: de scheerder ma. Clin Kidney J. 2019 Dec 10;14(1):429-431. doi: 10.1093/ckj/sfz165. eCollection 2021 Jan. Clin Kidney J. 2019. PMID: 33564449 Free PMC article.
Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.
Van Praet JT, Serrien B, Ausselet N, Darcis G, Demeester R, De Munter P, De Scheerder MA, Goffard JC, Libois A, Messiaen P, Yombi JC, Van Beckhoven D; Belgian HIV Cohort Study Group. Van Praet JT, et al. Among authors: de scheerder ma. J Acquir Immune Defic Syndr. 2023 Jun 1;93(2):e4-e5. doi: 10.1097/QAI.0000000000003175. J Acquir Immune Defic Syndr. 2023. PMID: 36787727 No abstract available.
Focal eosinophilic infiltration of the liver, benign or malignant?
Claeys W, Delie A, Smeets P, De Scheerder MA, Degroote H, Verhelst X, Van Vlierberghe H, Geerts A. Claeys W, et al. Among authors: de scheerder ma. Clin Case Rep. 2021 Aug 16;9(8):e04448. doi: 10.1002/ccr3.4448. eCollection 2021 Aug. Clin Case Rep. 2021. PMID: 34429979 Free PMC article.
25 results